Lilly's ED med Cialis sees sales suffer in wake of Viagra generics by Tracy Staton Wednesday, January 31, 2018 Eli Lilly's newer drugs are pumping out sales, especially its lead growth driver Trulicity, a diabetes drug. So much so, the company hiked its 2018 guidance.
Pfizer's Viagra finally set to face cheaper competition by Eric Sagonowsky Thursday, December 7, 2017 All these years after its initial approval, Pfizer's little blue pill Viagra is coming to the end of its patent life.
Sanofi wins tentative FDA approval for Humalog biosim by Eric Sagonowsky Friday, September 8, 2017 Eli Lilly has faced no shortage of trouble in diabetes recently, but the company now faces a new threat from rival Sanofi.
Lilly fends off Cialis generics with new patent settlement by Eric Sagonowsky Thursday, July 13, 2017 Eli Lilly’s storied erectile dysfunction med Cialis will keep exclusive protections a little while longer.
End of an era: Are Viagra and Cialis leaving TV advertising? by Beth Snyder Bulik Monday, July 10, 2017 Is it the end of a controversial era? Erectile dysfunction ads will no longer be seen during televised NFL football games, according to a new report.
Merck's Vytorin set for massive sales slide as generics hit by Eric Sagonowsky Friday, April 28, 2017 Merck’s cholesterol med Vytorin faces new competition from Teva and Impax Laboratories.
